Autolus Therapeutics Ltd (AUTL) - Total Liabilities

Latest as of March 2026: $418.24 Million USD

Based on the latest financial reports, Autolus Therapeutics Ltd (AUTL) has total liabilities worth $418.24 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Autolus Therapeutics Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Autolus Therapeutics Ltd - Total Liabilities Trend (2015–2025)

This chart illustrates how Autolus Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Autolus Therapeutics Ltd asset portfolio.

Autolus Therapeutics Ltd Competitors by Total Liabilities

The table below lists competitors of Autolus Therapeutics Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Kunshan Asia Aroma Corp. Ltd. SHE:301220	China	CN¥682.01 Million
Laxmi Organic Industries Limited NSE:LXCHEM	India	Rs12.67 Billion
Shenzhen King Explorer Science and Technology Corp Class A SHE:002917	China	CN¥1.10 Billion
BlackRock MIT II NYSE:BLE	USA	$368.24 Million
Electrosteel Castings Limited NSE:ELECTCAST	India	Rs40.16 Billion
Medprin Regenerative Medical Technologies Co. Ltd. SHE:301033	China	CN¥88.79 Million
Oncology Institute Inc NASDAQ:TOI	USA	$184.51 Million
Jiangxi Huawu Brake Co Ltd SHE:300095	China	CN¥1.36 Billion

Liability Composition Analysis (2015–2025)

This chart breaks down Autolus Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Autolus Therapeutics Ltd balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	5.80	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	3.84	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.79	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Autolus Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Autolus Therapeutics Ltd (2015–2025)

The table below shows the annual total liabilities of Autolus Therapeutics Ltd from 2015 to 2025.

Year	Total Liabilities	Change
2025-12-31	$410.94 Million	+15.63%
2024-12-31	$355.40 Million	+34.67%
2023-12-31	$263.91 Million	+37.74%
2022-12-31	$191.60 Million	+107.72%
2021-12-31	$92.24 Million	+9.54%
2020-12-31	$84.20 Million	+72.93%
2019-12-31	$48.69 Million	+289.01%
2018-12-31	$12.52 Million	0.00%
2018-09-30	$12.52 Million	+106.52%
2017-12-31	$6.06 Million	+73.52%
2016-12-31	$3.49 Million	+79.28%
2015-12-31	$1.95 Million	--

About Autolus Therapeutics Ltd

NASDAQ:AUTL USA Biotechnology

Market Cap

$503.01 Million

Market Cap Rank

#12236 Global

#3073 in USA

Share Price

$1.89

Change (1 day)

-2.58%

52-Week Range

$1.21 - $2.54

All Time High

$48.01